Monitor for FDA approval announcement of CGuard Prime 80 cm, which would trigger the 20-trading-day exercise window for the amended warrants and potentially provide launch capital. The company's ability to fund commercialization depends on warrant exercise and existing cash balances.
Price Chart
Executive Summary
InspireMD amended existing Series J and K warrants to align exercise with anticipated FDA approval of CGuard Prime 80 cm in Q4 2026. The amendments modify exercise price and termination date for ~14.3 million shares held by participating warrant holders, potentially providing additional capital for product launch without issuing new warrants.
Key Facts
- Amendments cover ~4.8M shares underlying Series J warrants and ~9.5M shares underlying Series K warrants held by participating holders.
- Exercise price for 50% of Series J shares and all Series K shares amended to $0.7674 per share (Nasdaq closing price on Sept 18, 2026).
- Termination date amended to earlier of May 15, 2028 or 20 trading days after FDA approval announcement for CGuard Prime 80 cm.
- No additional warrants or shares were issued in connection with the amendments.
- Company continues to anticipate FDA approval of CGuard Prime 80 cm in Q4 2026.
- CGuard Prime 80 cm is designed for TCAR procedures, which the company estimates at over 35,000 procedures annually in the US.
Financial Impact
Potential gross proceeds from exercise of amended warrants at $0.7674 per share could be up to ~$11.0M if all ~14.3M shares are exercised, but exercise is contingent on FDA approval and market conditions.
Risk Factors
- FDA approval of CGuard Prime 80 cm may not occur in Q4 2026 or at all, delaying or eliminating potential warrant exercise proceeds.
- Warrant holders may not exercise, leaving the company without expected capital for launch.
- Company has a history of losses and going concern risk; additional capital may still be needed.
- Voluntary recall of CGuard Prime 135 cm delivery system poses ongoing operational and financial risks.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3365503 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 21, 2026 5w ago | 8-K | $0.7500 $0.6895 | ▼ −8.07% | ▼ −7.05% | $0.4500 (−40.00%) |
Sep 21, 2026 5w ago | Press Release | $0.7500 $0.6895 | ▼ −8.07% | ▼ −7.05% | $0.4500 (−40.00%) |
Aug 17, 2026 10w ago | 8-K | $0.8798 $0.8699 | ▲ +1.13% | ▼ −0.07% | $0.4500 (+48.85%) |
Aug 17, 2026 10w ago | Press Release | $0.8798 $0.8699 | ▲ +1.13% | ▼ −0.07% | $0.4500 (+48.85%) |
Aug 10, 2026 11w ago | Press Release | $0.8500 $0.8816 | ▲ +3.72% | ▲ +4.12% | $0.4500 (−47.06%) |
Jul 29, 2026 12w ago | 8-K | $0.6718 $0.7222 | ▲ +7.50% | ▲ +3.88% | $0.4500 (−33.02%) |
Jul 23, 2026 13w ago | 8-K | $0.6835 $0.6718 | ▲ +1.71% | ▲ +2.09% | $0.4500 (+34.16%) |
Jul 2, 2026 16w ago | 8-K | $0.6990 $0.7121 | ▲ +1.87% | ▲ +0.94% | $0.4500 (−35.62%) |
May 21, 2026 22w ago | Insider Cluster | $1.00 $0.9900 | ▼ −1.00% | ▼ −2.66% | $0.4500 (−55.00%) |
May 15, 2026 23w ago | Insider Cluster | $1.05 $0.9500 | ▼ −9.52% | ▼ −11.14% | $0.4500 (−57.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers